MPs urge faster NHS access to Mounjaro

A cross-party committee of UK MPs has criticized the NHS rollout of Mounjaro, calling for an urgent acceleration and warning that the current approach could produce unequal access. The committee’s concern, as described by streamlinefeed.co.ke, is that access could depend on personal wealth rather than clinical need.

NHS England’s phased introduction is planned to reach about 220,000 people in England during the first three years. The outlet reports that approximately 3.4 million people in England meet the clinical criteria for the obesity treatment, making the planned initial reach about 6% of that eligible population.

The figures set out the scale of the gap that prompted the MPs’ criticism: a large clinically eligible population, but a much smaller number expected to receive treatment through the initial rollout. The committee’s warning is about the distribution of access, with wealth potentially shaping who can obtain treatment if NHS provision remains limited.

The drug is Mounjaro, the brand name for tirzepatide. The outlet describes it as a medicine that acts on GIP and GLP-1 receptors. Its account links the committee’s call for a faster rollout to the limited number of people included in the initial NHS plan, rather than presenting the planned coverage as matching the eligible population.

A more favourable commercial agreement is identified as a possible route to expanding the programme. According to streamlinefeed.co.ke, such an agreement could provide fiscal headroom to increase the eligible cohort beyond the initial 220,000 patients. The account does not state that an agreement has been reached or specify its terms.

The immediate issue raised by the committee is whether the NHS plan will extend access beyond its limited initial cohort. Its warning about a two-tier system rests on the prospect that personal resources, rather than clinical eligibility, could shape access while NHS provision reaches only a fraction of those meeting the criteria.